Classification of adverse events
Transfusion-related adverse events can be broadly classified as acute or delayed, and immunological or non-immunological.
- Immunological acute (<24 hours) adverse events including febrile non-haemolytic transfusion reactions (FNHTR), allergic reactions, acute haemolytic transfusion reaction (AHTR), ABO incompatibility, anaphylactic reaction, transfusion-related acute lung injury (TRALI)
- Non-immunological acute (<24 hours) adverse events including transfusion-associated circulatory overload (TACO)
- Immunological delayed (>24 hours) adverse events including delayed haemolytic transfusion reaction (DHTR), post-transfusion purpura (PTP), transfusion associated graft-versus-host disease (TA-GVHD)
- Non-immunological delayed (>24 hours) adverse events including transfusion transmitted infections (TTI)
Local reporting of adverse events
Once health service organisations recognise and clinically confirm a transfusion related adverse event, the event should be reported in the incident management and investigation system. The adverse event may need to be reported to the pathology service provider. In addition, any ‘near miss’ events should be included on the incident management and investigation system.
The next step depends on whether the adverse event is classified as a sentinel event or if it is determined to be the result of the:
- product or an immunological reaction to the product, or
- administration of the product.
The severity may be rated using a Severity Assessment Score (SAC) or an Incident Severity Rating (ISR) or other methodologies.
Sentinel events are events which are defined as any unanticipated event in a healthcare setting resulting in death or serious physical or psychological injury to a patient or patients. Sentinel events are legally required to be reported to the state/territory health department. ABO incompatibility is a sentinel event and therefore must be reported in line with local and state/territory reporting requirements.
ABO incompatibility should also be reported to the state/territory haemovigilance system and program in accordance with the national minimum dataset.
Product related or immunologically related adverse events
Product related adverse events are reactions that occur as a direct result of a problem with the product administered, for example: bacterial contamination, transfusion transmitted infection or incorrect labelling of product.
Immunological adverse events are events where a patient has an unexpected reaction to the blood product leading to an adverse immune response such as transfusion related acute lung injury (TRALI) or a febrile non-haemolytic reaction.
Events such as these are required to be notified to the manufacturer of that blood product, where in the case of fresh blood it is the Australian Red Cross Lifeblood (Lifeblood). It is then the responsibility of the manufacturer to determine if the event meets the requirements under the Good Manufacturing Practice Code to report the event to the Therapeutic Goods Administration For contact details and reporting requirements, refer to the product information sheet or Lifeblood Blood Component Information (BCI).
Reports of adverse events or defects in medicines in Australian can be made to the Therapeutic Goods Administration (TGA)
Administration related and near miss adverse events
Administration adverse reactions are reactions that occur as a result of the incorrect administration of blood products including: Transfusion Associated Circulatory Overload (TACO), incorrect dosage and near miss events.
Incorrect administration of blood products is not required to be reported to the manufacturer. However, the state/territory haemovigilance programs do report on this data. Therefore, any administration adverse event or near miss should be reported to the haemovigilance program as required by the National Safety and Quality Health Service Standard for Blood Management.
State/territory and national reporting of adverse events
All adverse events that meet the national and state/territory requirements should be reported to the state/territory haemovigilance system and program. The state/territory health department collates the data and reports the de-identified minimum dataset in line with the Australian Haemovigilance Minimum Data Set. The NBA analyses the data and publishes it in the Australian haemovigilance reports.
There are also requirements in some supplier contracts to report adverse events to the NBA, see the relevant contract under Contracts with Suppliers.